07 July 2025
07 July 2025
The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.
By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.
The two organisations provide sustainable access to transformative treatments for children in need..
uUTIs are caused by strains of Proteus mirabilis, Escherichia coli and Staphylococcus saprophyticus.
More than half of the top 15 pharma companies are expected to face challenges in managing the patent cliff.
Clinical trials have demonstrated that both biosimilars match the reference product's quality, safety and efficacy standards.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
